Targeted nanoliposomes to improve enzyme replacement therapy of Fabry disease
Science Advances · 2024
DOI: 10.1126/sciadv.adq4738 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, 2024. Verfasst von Judit Tomsen-Melero und 25 weiteren Autor:innen. Beteiligte Einrichtung: Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina, Instituto de Salud Carlos III, Madrid, Spain. Hauptthemen laut MEDLINE: Fabry Disease, Enzyme Replacement Therapy, Liposomes, alpha-Galactosidase. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
The central nervous system represents a major target tissue for therapeutic approach of numerous lysosomal storage disorders. Fabry disease arises from the lack or dysfunction of the lysosomal alpha-galactosidase A (GLA) enzyme, resulting in substrate accumulation and multisystemic clinical manifestations. Current enzyme replacement therapies (ERTs) face limited effectiveness due to poor enzyme biodistribution in target tissues and inability to reach the brain. We present an innovative drug delivery strategy centered on a peptide-targeted nanoliposomal formulation, designated as nanoGLA, engineered to selectively deliver a recombinant human GLA (rhGLA) to target tissues. In a Fabry mouse model, nanoGLA demonstrated improved efficacy, inducing a notable reduction in Gb3 deposits in contrast to non-nanoformulated GLA, even in the brain, highlighting the potential of the nanoGLA to address both systemic and cerebrovascular manifestations of Fabry disease. The EMA has granted the Orphan Drug Designation to this product, underscoring the potential clinical superiority of nanoGLA over authorized ERTs and encouraging to advance it toward clinical translation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina, Instituto de Salud Carlos III, Madrid, Spain.
- Institut de Ciència de Materials de Barcelona, ICMAB-CSIC, Campus UAB, 08193 Bellaterra, Spain.
- Clinical Biochemistry, Drug Delivery & Targeting (CB-DDT), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.
- Nanomol Technologies SL, Campus de la UAB, 08193 Bellaterra, Spain.
- Functional Validaton & Preclinical Research (FVPR)/U20 ICTS Nanbiosis, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.
- Institut de Química Avançada de Catalunya (IQAC-CSIC), c/ Jordi Girona 18-26, 08034 Barcelona, Spain.
ORCID-Profile: Judit Tomsen-Melero, Marc Moltó-Abad, Josep Merlo-Mas, Zamira V Díaz-Riascos, Edgar Cristóbal-Lecina, Thomas Altendorfer-Kroath, Inbal Ionita, Jan Skov Pedersen, Aida Carreño, José L Corchero, Daniel Pulido, Josefina Casas, Jaume Veciana, Simó Schwartz, Santi Sala, Thomas Birngruber, Miriam Royo, Alba Córdoba, Nora Ventosa, Ibane Abasolo, Elisabet González-Mira
Zitieren
APA
Tomsen-Melero, J., Moltó-Abad, M., Merlo-Mas, J., Díaz-Riascos, Z. V., Cristóbal-Lecina, E., Soldevila, A., Altendorfer-Kroath, T., Danino, D., Ionita, I., Pedersen, J. S., Snelling, L., Clay, H., Carreño, A., Corchero, J. L., Pulido, D., Casas, J., Veciana, J., Simó Schwartz, Sala, S., …, & González-Mira, E. (2024). Targeted nanoliposomes to improve enzyme replacement therapy of Fabry disease. Science Advances. https://doi.org/10.1126/sciadv.adq4738
Vancouver
Tomsen-Melero J, Moltó-Abad M, Merlo-Mas J, Díaz-Riascos ZV, Cristóbal-Lecina E, Soldevila A, et al. Targeted nanoliposomes to improve enzyme replacement therapy of Fabry disease. Science Advances. 2024. doi:10.1126/sciadv.adq4738
BibTeX
@article{TomsenMelero2024,
author = {Tomsen-Melero, Judit and Moltó-Abad, Marc and Merlo-Mas, Josep and Díaz-Riascos, Zamira V and Cristóbal-Lecina, Edgar and Soldevila, Andreu and Altendorfer-Kroath, Thomas and Danino, Dganit and Ionita, Inbal and Pedersen, Jan Skov and Snelling, Lyndsey and Clay, Hazel and Carreño, Aida and Corchero, José L and Pulido, Daniel and Casas, Josefina and Veciana, Jaume and Simó Schwartz and Sala, Santi and Font, Albert and Birngruber, Thomas and Royo, Miriam and Córdoba, Alba and Ventosa, Nora and Abasolo, Ibane and González-Mira, Elisabet},
title = {Targeted nanoliposomes to improve enzyme replacement therapy of Fabry disease},
journal = {Science Advances},
year = {2024},
doi = {10.1126/sciadv.adq4738}
}
EUVIMED